Colcrys (Colchicine) Patent Expiration, LOE Window & CMS Spending

Colcrys (Colchicine) by Ar Holding: FDA Orange Book LOE 2029-02-17, 12 AB generics, $461K 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorAr Holding
FDA Application & PathwayN022351 (NDA)
Exclusivity / Cliff HorizonNear-Term Cliff (2028-2030)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2029-02-17
Orange Book Patents (*PED Extensions)17 patents (0 *PED)
Active AB-Rated Generic Competitors12
2024 CMS Total Public Spend$461K
2024 Medicare Part D Spend$236K
2024 Medicaid Spend$225K
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel